Wholly Owned Pipeline
PureTech's Wholly Owned Programs are designed to harness key immunological, fibrotic and lymphatic system mechanisms. These novel classes of immunomodulatory drugs are designed to treat serious diseases, including lung dysfunction, immuno-oncology, lymphatic, neurological and neuropsychological disorders.
Wholly Owned Pipeline
2 | IPF | ~130K U.S. |
Therapeutic candidate being advanced for the potential treatment of conditions involving inflammation and fibrosis, including lung disease (idiopathic pulmonary fibrosis (IPF) and Long COVID respiratory complications and related sequelae) and disorders of lymphatic flow, such as lymphedema.
2 | Long COVID respiratory complications & related sequelae | >292M Worldwide |
Therapeutic candidate being advanced for the potential treatment of conditions involving inflammation and fibrosis, including lung disease (idiopathic pulmonary fibrosis (IPF) and Long COVID respiratory complications and related sequelae), and disorders of lymphatic flow, such as lymphedema.
2a | Lymphatic flow disorders, including lymphedema | ~1M U.S. |
Therapeutic candidate being advanced for the potential treatment of conditions involving inflammation and fibrosis, including lung disease (idiopathic pulmonary fibrosis (IPF) and Long COVID respiratory complications and related sequelae), and disorders of lymphatic flow, such as lymphedema.
1 | Solid tumors | >50K/year U.S. (Metastatic CRC) |
Fully human monoclonal antibody designed to inhibit the activity of galectin-9, a key molecule expressed by tumors and immune cells and shown to suppress the immune system from recognizing and destroying cancer cells, which we are developing for difficult-to-treat cancer indications with poor survival rates, including pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC) and cholangiocarcinoma (CCA).
Preclinical | Solid tumors | >50K/year U.S. (Metastatic CRC) |
Fully human IgG1 monoclonal antibody directed against the delta-1 chain of T cells bearing gamma delta-1 T cell receptors that we have designed to target and deplete immunosuppressive gamma delta-1 T cells in cancer.
1 | Neurological indications |
LYT-300 is designed to unlock the validated biology of allopregnanolone to potentially offer a new, oral treatment option for a range of conditions where there is significant patient need. Allopregnanolone is a natural neurosteroid that is a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors, which are known to play a key biological role in depression, epilepsy and other neurological and neuropsychological conditions. Natural allopregnanolone has poor oral bioavailability, thus limiting its development as a therapeutic. An injectable formulation of allopregnanolone is approved by the United States Food and Drug Administration (FDA) as a 60-hour infusion for the treatment of post-partum depression, though the method of administration has limitations.
Anti-inflammatory
Preclinical | Inflammatory bowel disease | ~3M U.S. |
Therapeutic candidate being advanced for the potential treatment of inflammatory bowel disease (IBD) that is designed with a dual mechanism of action to provide both mucosal repair and targeted resolution of tissue inflammation.
Preclinical | Interstitial cystitis/Bladder pain syndrome | ~4-12M U.S. |
Therapeutic candidate being developed for the potential treatment of interstitial cystitis/bladder pain syndrome (IC/BPS) that is designed to selectively treat IC/BPS while minimizing the potential for related systemic toxicities by selectively targeting API pharmacology to inflamed tissue.
| Phase completed | Phase in progress | Registration-enabling studies to begin in 1H2022 |
1 The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether our wholly-owned therapeutic candidates are safe and effective. No regulatory agency has made any such determination that our wholly-owned therapeutic candidates are safe or effective for use by the general public for any indication. On July 23, 2021, Imbrium Therapeutics exercised its option to license LYT-503/IMB-150 pursuant to which it is responsible for all future development activities and funding for LYT-503/IMB-150.
2 Long COVID is a term being used to describe the emerging and persistent complications following the resolution of COVID-19 infection, also known as post-acute COVID-19 syndrome (PACS).
The BIG Idea - Moving medicine forward at PureTech
